Canada will ship 800 vials of its experimental Ebola virus disease vaccine, VSV-EBOV, to the World Health Organization, Ottawa announced Saturday. The Ebola vaccine will be sent in three shipments. Human clinical trials of VSV-EBOV began Monday after previously being shown effective in other primates.
加拿大將運送800瓶埃博拉試驗性疫苗VSV-EBOV給世界衛生組織。這批疫苗將被分成三批運送。VSV-EBOV疫苗之前在其他靈長類動物身上試驗後被證明有效，從本周一開始將對其進行人體臨床試驗。
“This vaccine, the product of many years of scientific research and innovation, could be an important tool in curbing the outbreak. We will continue to work closely with the WHO to address some of the ethical and logistical issues around using this experimental vaccine in the fight against Ebola,” Gregory Taylor, Canada’s chief public health officer, said in a statement.
加拿大首席衛生官員格利高裏·泰勒稱：“該(gai)疫(yi)苗(miao)是(shi)多(duo)年(nian)科(ke)學(xue)研(yan)究(jiu)和(he)不(bu)斷(duan)創(chuang)新(xin)的(de)結(jie)果(guo)，可(ke)以(yi)成(cheng)為(wei)應(ying)對(dui)此(ci)次(ci)埃(ai)博(bo)拉(la)疫(yi)情(qing)的(de)重(zhong)要(yao)工(gong)具(ju)。我(wo)們(men)將(jiang)會(hui)繼(ji)續(xu)加(jia)強(qiang)與(yu)世(shi)衛(wei)組(zu)織(zhi)的(de)緊(jin)密(mi)合(he)作(zuo)，以(yi)應(ying)對(dui)在(zai)使(shi)用(yong)埃(ai)博(bo)拉(la)試(shi)驗(yan)性(xing)疫(yi)苗(miao)時(shi)所(suo)產(chan)生(sheng)的(de)倫(lun)理(li)道(dao)德(de)和(he)後(hou)勤(qin)保(bao)障(zhang)問(wen)題(ti)。”
Each shipment of VSV-EBOV will be packed in a special container with dry ice, at a temperature of -80 degrees Celsius, or -112 degrees Fahrenheit. The vaccine was developed at the National Microbiology Laboratory in Canada. The government has licensed the NewLink Genetics Corp. to produce VSV-EBOV in an attempt to help stop the spread of Ebola in West Africa.
三批VSV-EBOV疫苗將被分別裝入三個特殊的容器中，容器中盛有幹冰

，以保證溫度在零下80攝氏度（即零下112華氏度）。VSV-EBOV疫苗是在加拿大國家微生物實驗室中研發出來的。加政府授權生物技術公司NewLink Genetics Corp生產
，希望該疫苗能幫助阻止埃博拉病毒在西非的蔓延。
The vaccine is a combination of a weakened version of the vesicular stomatitis virus, or VSV, found in animals including cattle and horses, and protein from the Ebola virus. VSV is zoonotic, meaning it can be transferred from animals to humans. Infected humans develop flulike symptoms, according to the University of Wisconsin School of Veterinary Medicine. The VSV-EBOV vaccine triggers an immune system response that produces antibodies against the Ebola protein, similar to the way a flu shot works.
VSV-EBOV疫苗是由在牛
、馬等動物身上提取的水皰性口炎病毒（即VSV）和埃博拉病毒蛋白質組合而成。VSV是一種人畜共患病毒
，也就是說它可以在動物和人之間傳播。根據威斯康星大學獸醫學院的研究，感染VSV的人會表現出流感的症狀。VSV-EBOV疫苗能夠誘發人體免疫係統產生應對埃博拉病毒蛋白質的抗體，這和流感疫苗的原理類似。
Clinical trials are under way at the Walter Reed Army Institute of Research, headquartered in Silver Spring, Md. Results will not be available until December. Canada has been at the forefront of Ebola drug development, with TKM-EBOLA and ZMapp also being developed in Canada with the help of U.S. funding and partnerships. The latter was recently used on the Spanish nurse Teresa Romero, who contracted the virus Oct. 6. Meanwhile, a second vaccine is also in the works in Canada.
該疫苗的臨床試驗正在總部位於銀泉市的沃爾特裏德陸軍研究所中進行。具體結果要到12月份才能知曉。在埃博拉藥物研製方麵加拿大一直處於最前沿，TKM-EBOLA和ZMapp疫苗都是在美國資金和人員的幫助下在加拿大被研發出來的。其中ZMapp疫苗最近已被用在10月6日感染埃博拉病毒的西班牙護士特裏薩身上。另外，加拿大仍有一種疫苗正在研發中。
“Canada views this experimental Ebola vaccine as a global resource, and, in the interest of global public health, we are sharing it with our international partners to help address the Ebola outbreak in West Africa,” Canadian Health Minister Rona Ambrose said in a statement.
加拿大衛生部長羅娜·安布羅絲曾表示：“加jia拿na大da把ba這zhe支zhi埃ai博bo拉la實shi驗yan性xing疫yi苗miao看kan做zuo是shi全quan球qiu資zi源yuan，這zhe關guan係xi到dao全quan世shi界jie人ren類lei健jian康kang的de共gong同tong利li益yi。我wo們men會hui把ba疫yi苗miao和he其qi他ta國guo家jia分fen享xiang，以yi此ci來lai幫bang助zhu應ying對dui西xi非fei的de埃ai博bo拉la疫yi情qing。”
The first shipment of the VSV-EBOV vaccine to WHO in Geneva will be made Monday.
第一批VSV-EBOV疫苗將於周一到達日內瓦的世界衛生組織。